0001209191-20-028940.txt : 20200513 0001209191-20-028940.hdr.sgml : 20200513 20200513180011 ACCESSION NUMBER: 0001209191-20-028940 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200511 FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daly James M CENTRAL INDEX KEY: 0001560782 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 20874625 MAIL ADDRESS: STREET 1: INCYTE CORPORATION EXPERIMENTAL STATION STREET 2: RTE 141 & HENRY CLAY RD. BLDG E336 CITY: WILMINGTON STATE: DE ZIP: 19880 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DRIVE STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-11 0 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001560782 Daly James M C/O ACADIA PHARMACEUTICALS INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 1 0 0 0 Common Stock 2020-05-11 4 M 0 11250 25.24 A 11250 D Common Stock 2020-05-11 4 M 0 15000 27.25 A 26250 D Common Stock 2020-05-11 4 S 0 26250 51.1306 D 0 D Stock Option (Right to Buy) 25.24 2020-05-11 4 M 0 11250 0.00 D 2029-06-26 Common Stock 11250 11250 D Stock Option (Right to Buy) 27.25 2020-05-11 4 M 0 15000 0.00 D 2027-06-12 Common Stock 15000 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.975 to $51.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant. The option is fully vested and exercisable. /s/ Austin D. Kim, Attorney-in-Fact 2020-05-13